MedTrace Logo

Efficacy and Safety of TDF+3TC+EFV in Adults With HIV/HBV Coinfection

NCT01751555 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2013-06-28

No results posted yet for this study

Summary

This is a Phase 4 single-arm, post-marketing clinical trial evaluating the efficacy and safety of tenofovir disoproxil fumarate, lamivudine and efavirenz in adults with human immunodeficiency virus-1 and hepatitis B virus coinfection.

Conditions

Interventions

DRUG

Regimen:TDF+3TC+EFV

TDF+3TC+EFV for HIV/HBV co-infection

Sponsors & Collaborators

  • Gilead Sciences

    collaborator INDUSTRY

  • National Center for AIDS/STD Control and Prevention, China CDC

    lead OTHER_GOV

Principal Investigators

  • Fujie ZHANG, MD · National Center for AIDS/STD Control and Prevention, China CDC

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-02-28
Primary Completion
2013-06-30
Completion
2013-06-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01751555 on ClinicalTrials.gov